What kind of inhibitor is Duvelisib?

Duvelisib (Duvelisib) is a phospholipase inhibitor that mainly inhibits phosphatidylinositol3 kinase (PI3K) and phospholipase D (PLD) and other signaling pathways to achieve its anti-cancer effect.

1.PI3KInhibition: PI3K is a protein kinase involved in regulating important biological processes such as cell growth, differentiation, survival and metabolism. Abnormally activated PI3K pathway is closely related to the development and progression of various malignant tumors such as leukemia and lymphoma. Duvelicet works by inhibiting multiple PI3K isoforms, including α type, β type, δ type and γ type interfere with the activation of this signaling pathway, thereby limiting the growth and spread of cancer cells.

2.PLDInhibition: PLD is the abbreviation of phospholipase D, which is involved in the metabolism and signaling of cell membranes. Duveliced u200bu200balso affects cell signaling by inhibiting PLD, further slowing down the abnormal proliferation and metastasis of cancer cells.

The uniqueness of Duveliced is that it affects both the PI3K and PLD signaling pathways. This dual inhibition mechanism is expected to play a role in the treatment of multiple types of leukemias and lymphomas. However, patients need to closely follow their doctor's advice when using duvelised, as the drug may cause a range of adverse reactions that require effective management. Duveliside represents a novel inhibitor of leukocyte signaling pathways, providing a new treatment option for patients who are not suitable for traditional treatments or have already experienced relapse.

The original drug of Duvelisel Capsules has been launched in China, but it is not covered by medical insurance. Patients can buy it domestically at a price of more than 20,000 yuan. For specific prices, please consult the local hospital pharmacy.